ArticleCurrent protocols in immunology2015
Mouse model for pre-clinical study of human cancer immunotherapy.
Article in Current protocols in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice.Nature communications · 2025Article
- A functional comparison of two transplantable syngeneic mouse models of melanoma: B16F0 and YUMM1.7.Biology open · 2025Article
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Intravital imaging of pulmonary lymphatics in inflammation and metastatic cancer.The Journal of experimental medicine · 2025Article
- Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity.Cell · 2025Article
- PTEN enhances the radiosensitivity of melanoma by inhibiting DNA-PKcs.Frontiers in cell and developmental biology · 2025Article
- Intravital imaging of pulmonary lymphatics in inflammation and metastatic cancer.bioRxiv : the preprint server for biology · 2024Article
- Article
- Structural basis for self-discrimination by neoantigen-specific TCRs.Nature communications · 2024Article
- Structural Basis for Self-Discrimination by Neoantigen-Specific TCRs.Research square · 2023Article
- Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.Journal for immunotherapy of cancer · 2022Article
- In Vitro Cell Impedance Assay to Examine Antigen-Specific T-Cell-Mediated Melanoma Cell Killing to Support Cancer Immunotherapy Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer.Scientific reports · 2021Article
- Synergistic Effects of Exercise Training and Vitamin D Supplementation on Mitochondrial Function of Cardiac Tissue, Antioxidant Capacity, and Tumor Growth in Breast Cancer in Bearing-4T1 Mice.Frontiers in physiology · 2021Article
- Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.Cancer research · 2019Article
- Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.Journal for immunotherapy of cancer · 2017Article
- In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model.Journal of visualized experiments : JoVE · 2017Article
- AImmunoHorizons · 2017Article
- Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.Advanced biosystems · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
This unit describes protocols for developing tumors in mice, including subcutaneous growth, pulmonary metastases of B16 melanoma, and spontaneous melanoma in B-Raf V600E/PTEN deletion transgenic mouse models. Two immunization methods to prevent B16 tumor growth are described using B16.GM-CSF and recombinant vaccinia virus. A therapeutic approach is also included that uses adoptive transfer of tumor antigen-specific T cells. Methods including CTL induction, isolation, testing, and genetic modification of mouse T cells for adoptive transfer by using retrovirus-expressing genes of interest are provided. Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, tumor imaging technique, and use of recombinant viruses for vaccination, are discussed together with safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.